Bafna Pharmaceuticals Share Price

    NSE
    89.38
    -0.68 (1.12%)
    BAFNAPH • 04 Jul, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    -1.81%

    3Y Annualised Return

    -7.78%

    5Y Annualised Return

    32.13%

    The current prices are delayed, login or Open Demat Account for live prices.

    Bafna Pharmaceuticals Stock Performance

    1W Return11.47
    1Y Return-2.74
    Today's Low87.5
    Prev. Close90.06
    Mkt Cap (Cr.)211.04
    1M Return21.95
    3Y Return-22.43
    52-Week High96
    Open93.49
    PE Ratio33.63
    6M Return8.82
    Today's High93.49
    52-Week Low69
    Face Value10

    Bafna Pharmaceuticals Company background

    Founded in: 1995
    Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a. Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern. During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products. During 2006, Bafna has set up a 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. This facility has been set up as per revised Schedule M under the Drugs and Cosmetics Act, 1947. The unit has been WHO GMP certified and also ISO 9000 certified. The manufactured products in this factory catered to the markets of Srilanka, Ghana and Ukraine.Bafna was carrying on contract manufacturing for M/s Croslands Pvt. Ltd, a Mumbai based Pharmaceutical Company during the period 1994 to 2000. The companys first product was registered in Srilanka in 1995 and the company made its first export during the same year. Presently around 57 products of the company are registered in Srilanka. During the year 2000 Bafna registered 3 of its products in Lao and in the year 2006, 4 products were registered in Ukraine. During 2007, Bafna registered 1 product in Ghana. The products registered by the company cover all the therapeutic segments. In the year 2003, the Government of India granted the Export House status to the company. The company received the Best Supplier award from the Srilankan Government during 2005.After establishing itself in the non regulated market, the company decided to enter into a more lucrative and regulated market of Europe. Towards this objective, the company started construction of a new state of art facility at Grantlayon village, near Red hills, Chennai for the manufacture of Non Betalactum products in solid oral dosage form during 2005. This unit is a 100% EOU unit. The factory was completed and inaugurated on October 2, 2006. This new plant has been set up with guidelines as laid down in European GMP. The machineries installed in the new facility of the company are Programmable Logic Controller and all the contact parts are made of stainless steel. This leads to consistent quality of products produced with no contamination. The Auto Coater machinery used in the unit is imported from Korea and Camera system for detection of unfilled product is imported from USA. The company has entered into an agreement with an UK based company Somex Pharma for sale of cholesterol lowering agent products to be manufactured by Bafna at this unit. A fullscale commercial production would be commenced in the new unit once approval of MHRA is received. Presently company is validating the equipments and process at this unit and taking validation batches for trail run.The Company launched Raricap to domestic market in FY 12. It again launched three more brands namely BSF (Dietary Supplement), Molev (Antiasthamics) and Lopih (Lowering pregnancy induced hypertension) segments for women wellness. In 2022, it expanded operations and set up manufacturing facilities in Chennai, India, with UKMHRA TGA Australia accreditations, with round the year exports to prestigious Regulated Markets and Emerging markets.

    As of 04 Jul, 2025, Bafna Pharmaceuticals share price is ₹89.2. The stock opened at ₹93.5 and had closed at ₹90.1 the previous day. During today’s trading session, Bafna Pharmaceuticals share price moved between ₹87.50 and ₹93.49, with an average price for the day of ₹90.50. Over the last 52 weeks, the stock has recorded a low of ₹69.00 and a high of ₹96.00. In terms of performance, Bafna Pharmaceuticals share price has increased by 8.8% over the past six months and has declined by 1.81% over the last year.

    Read More
    Bafna Pharmaceuticals SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹64,41,302 (-0.90%)

    Daily SIP of 25,000 would have become 64,41,302 in 1 year with a gain of -58,697 (-0.90%)

    View details of Market Depth

    Bafna Pharmaceuticals Fundamental

    Market Cap (in crs)

    211.04

    Face Value

    10

    Turnover (in lacs)

    9.39

    Key Metrics

    Qtr Change %
    29.29% Gain from 52W Low
    20.5
    Dividend yield 1yr %
    0

    Bafna Pharmaceuticals Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Bafna Pharmaceuticals Quarterly Revenue
    Mar 2020Dec 2019Sep 2019Jun 2019Sep 2018
    13.13 Cr
    10.93 Cr
    11.57 Cr
    6.85 Cr
    8.84 Cr
    Bafna Pharmaceuticals Yearly Revenue
    Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
    42.73 Cr
    44.01 Cr
    78.5 Cr
    66.1 Cr
    87.3 Cr
    143.68 Cr
    Bafna Pharmaceuticals Quarterly Net Profit/Loss
    Mar 2020Dec 2019Sep 2019Jun 2019Sep 2018
    0.6 Cr
    -22.33 Cr
    -0.59 Cr
    -2.13 Cr
    -1.28 Cr
    Bafna Pharmaceuticals Yearly Net Profit/Loss
    Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
    -24.44 Cr
    -18.35 Cr
    -16.91 Cr
    -19.46 Cr
    -15.14 Cr
    6.22 Cr

    Top Mutual Fund Invested in Bafna Pharmaceuticals

    Promoter
    75%
    Foreign Institutions
    8.5%
    Public
    16.5%
    Promoter
    88.3%
    Public
    11.7%
    Promoter
    88.3%
    Public
    11.7%
    Promoter
    88.3%
    Public
    11.7%
    Promoter
    88.3%
    Public
    11.7%
    Promoter
    88.4%
    Public
    11.6%

    Bafna Pharmaceuticals Technical Analysis

    Moving Averages Analysis
    89.38
    Current Price
    Bullish Moving Averages
    16
    Bearish Moving Averages
    0
    5Day EMA
    87.80
    10Day EMA
    84.60
    12Day EMA
    83.60
    20Day EMA
    81.00
    26Day EMA
    79.90
    50Day EMA
    78.10
    100Day EMA
    77.70
    200Day EMA
    79.40
    5Day SMA
    88.60
    10Day SMA
    83.00
    20Day SMA
    79.00
    30Day SMA
    77.40
    50Day SMA
    76.80
    100Day SMA
    76.60
    150Day SMA
    78.00
    200Day SMA
    78.80
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    7454 Rs
    15707 Rs
    Week Rs
    17320 Rs
    26555 Rs
    Month Rs
    6923 Rs
    9022 Rs
    90.07
    Pivot
    Resistance
    First Resistance
    92.63
    Second Resistance
    96.06
    Third Resistance
    98.62
    Support
    First Support
    86.64
    Second support
    84.08
    Third Support
    80.65
    Relative Strength Index
    72.54
    Money Flow Index
    56.25
    MACD
    3.66
    MACD Signal
    2.07
    Average True Range
    3.80
    Average Directional Index
    31.64
    Rate of Change (21)
    19.76
    Rate of Change (125)
    7.79
    Name
    Holding Percent
    M7 GLOBAL FUND PCC-AERION
    2.91
    M7 GLOBAL FUND PCC - CELL DEWCAP FUND
    2.86
    ZEAL GLOBAL OPPORTUNITIES FUND
    2.76

    Bafna Pharmaceuticals Latest News

    30 JUN 2025 | Monday

    Bafna Pharmaceuticals Ltd - 532989 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    26 JUN 2025 | Thursday

    Bafna Pharmaceuticals Ltd - 532989 - Closure of Trading Window

    24 JUN 2025 | Tuesday

    Bafna Pharmaceuticals Ltd - 532989 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Re-Constitution Of Committees

    View More

    Bafna Pharmaceuticals Share Price FAQs

    Bafna Pharmaceuticals share price is ₹89.38 in NSE and ₹89.45 in BSE as on 4/7/2025.

    Bafna Pharmaceuticals share price in the past 1-year return was -2.73. The Bafna Pharmaceuticals share hit a 1-year low of Rs. 69 and a 1-year high of Rs. 96.

    The market cap of Bafna Pharmaceuticals is Rs. 211.04 Cr. as of 4/7/2025.

    The PE ratios of Bafna Pharmaceuticals is 33.63 as of 4/7/2025.

    The PB ratios of Bafna Pharmaceuticals is 2.49 as of 4/7/2025

    You can easily buy Bafna Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Bafna Pharmaceuticals share price is ₹96 and ₹69 as of 4/7/2025.

    Please be aware that Bafna Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.53
    +0.26 (+0.40%)
    139.24
    -0.46 (-0.33%)
    689.05
    -1.35 (-0.20%)
    2,599.10
    -12.10 (-0.46%)
    166.67
    -0.85 (-0.51%)
    391.40
    +0.75 (+0.19%)
    163.01
    -2.90 (-1.75%)
    261.40
    +0.55 (+0.21%)
    427.55
    +1.30 (+0.30%)
    401.00
    +1.10 (+0.28%)
    Top Gainers
    925.30
    +15.15 (+1.66%)
    1,640.70
    +22.00 (+1.36%)
    1,307.40
    +16.10 (+1.25%)
    1,442.80
    +16.90 (+1.19%)
    270.05
    +3.00 (+1.12%)
    Top Losers
    5,456.00
    -735.00 (-11.87%)
    163.01
    -2.90 (-1.75%)
    5,629.00
    -87.00 (-1.52%)
    1,655.20
    -16.70 (-1.00%)
    12,646.00
    -106.00 (-0.83%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -